US EditionPublished • loading... • Updated
Presidential Executive Order Validates Defloria's Strategy in Pharmaceutical Cannabinoid Drug Development
Summary by pressreach.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development - PressReach
DeFloria Advancing Charlotte’s Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug LOUISVILLE, Colo. and WASHINGTON, Dec. 19, 2025 /PRNewswire/ – DeFloria Inc., a botanical drug development Company recognizes the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, as a critical accelerator for cannabinoid medical innovation and regulatory reform. DeFloria is advanci…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
